Thrombocythemia Clinical Trials

1 recruiting

Thrombocythemia Trials at a Glance

29 actively recruiting trials for thrombocythemia are listed on ClinicalTrialsFinder across 6 cities in 40 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in New York, Paris, and Ann Arbor. Lead sponsors running thrombocythemia studies include Merck Sharp & Dohme LLC, University Hospital, Angers, and University Hospital, Brest.

Browse thrombocythemia trials by phase

Treatments under study

About Thrombocythemia Clinical Trials

Looking for clinical trials for Thrombocythemia? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Thrombocythemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Thrombocythemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 29 trials

Recruiting
Phase 3

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Essential Thrombocythemia
Merck Sharp & Dohme LLC300 enrolled167 locationsNCT06456346
Recruiting
Phase 3

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Essential Thrombocythemia
Merck Sharp & Dohme LLC340 enrolled163 locationsNCT06079879
Recruiting
Phase 1Phase 2

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Myelodysplastic SyndromesMyelofibrosisAnemia+4 more
Disc Medicine, Inc150 enrolled24 locationsNCT05320198
Recruiting
Phase 2

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Myelodysplastic/Myeloproliferative NeoplasmPolycythemia VeraPrimary Myelofibrosis+5 more
National Cancer Institute (NCI)62 enrolled30 locationsNCT06661915
Recruiting
Phase 2

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline68 enrolled33 locationsNCT06517875
Recruiting
Phase 3

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

MyelofibrosisPolycythemia VeraPrimary Myelofibrosis+3 more
Merck Sharp & Dohme LLC400 enrolled21 locationsNCT06351631
Recruiting

Registry Platform Myelofibrosis and Anemia

MyelofibrosisAnemiaPrimary Myelofibrosis+4 more
iOMEDICO AG200 enrolled1 locationNCT06976918
Recruiting
Phase 2

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Myelodysplastic SyndromeMyelofibrosisPolycythemia Vera+2 more
University of Southern California30 enrolled2 locationsNCT06063486
Recruiting
Phase 3

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Polycythemia VeraEssential ThrombocythemiaPrefibrotic/Early Primary Myelofibrosis+1 more
University Hospital, Brest1,308 enrolled42 locationsNCT05198960
Recruiting
Phase 2

Study of Canakinumab in Patients With Myelofibrosis

Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisET-MF+2 more
John Mascarenhas14 enrolled8 locationsNCT05467800
Recruiting
Phase 2

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Acute Myeloid LeukemiaMyelodysplastic SyndromeMyeloproliferative Neoplasm+6 more
University of Washington25 enrolled1 locationNCT04282187
Recruiting
Phase 1Phase 2

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

MyelofibrosisMyeloproliferative NeoplasmPolycythemia Vera+2 more
University of California, Irvine27 enrolled2 locationsNCT05123365
Recruiting
Not Applicable

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)

Myeloproliferative NeoplasmEssential ThrombocythemiaPrimary Myelofibrosis, Prefibrotic Stage+1 more
University Hospital, Angers260 enrolled10 locationsNCT04942080
Recruiting
Phase 3

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum399 enrolled207 locationsNCT03165734
Recruiting

National Longitudinal Cohort of Hematological Diseases

Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome+14 more
Institute of Hematology & Blood Diseases Hospital, China2,300 enrolled1 locationNCT04645199
Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Polycythemia VeraET (Essential Thrombocythemia)Polycythemia Vera (PV)
MPN Research Foundation5,000 enrolled2 locationsNCT07362225
Recruiting
Phase 2

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Polycythemia VeraEssential Thrombocythemia
Massachusetts General Hospital60 enrolled4 locationsNCT04644211
Recruiting
Phase 2

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Myelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Icahn School of Medicine at Mount Sinai26 enrolled9 locationsNCT05835466
Recruiting

A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes

Polycythemia VeraThrombocythemia
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS678 enrolled25 locationsNCT07203768
Recruiting
Not Applicable

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes

Myeloproliferative NeoplasmPolycythemia VeraPrimary Myelofibrosis+1 more
University Hospital, Angers70 enrolled3 locationsNCT06361641